BCRX
Biocryst Pharmaceuticals Inc
NASDAQ · Biotechnology
$6.38
+0.14 (+2.24%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 540.87M | 380.74M | 351.53M | 328.14M | 317.43M |
| Net Income | -106,656,788 | -67,570,821 | -74,073,813 | -56,674,354 | -58,578,347 |
| EPS | — | — | — | — | — |
| Profit Margin | -19.7% | -18.7% | -21.1% | -17.3% | -18.5% |
| Rev Growth | +42.1% | +42.1% | +19.3% | +7.1% | +23.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 534.86M | 534.86M | 105.48M | 92.91M | 118.94M |
| Total Equity | 256.38M | 256.38M | 612.82M | 596.71M | 574.48M |
| D/E Ratio | 2.09 | 2.09 | 0.17 | 0.16 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -1,562,645 | -1,044,989 | -81,791,824 | -75,730,538 | -85,752,478 |
| Free Cash Flow | — | — | -74,299,092 | -52,199,092 | -47,303,254 |